Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study.

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study : A randomized controlled trial.

[1]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[2]  D R Shapiro,et al.  Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). , 2000, Circulation.

[3]  S. Ellenberg,et al.  Neonatal deaths after hepatitis B vaccine: the vaccine adverse event reporting system, 1991-1998. , 1999, Archives of pediatrics & adolescent medicine.

[4]  D. Lauderdale,et al.  Hepatitis B vaccination among children in inner-city public housing, 1991-1997. , 1999, JAMA.

[5]  F. Ragmin.  Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study , 1999, The Lancet.

[6]  B. Hoogwerf,et al.  Long-Term Effects on Clinical Outcomes of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation in the Post Coronary Artery Bypass Graft Trial , 2000 .

[7]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[8]  D. Cox.  Regression Models and Life-Tables , 1972 .

[9]  V. Coronado,et al.  Association between administration of hepatitis B vaccine at birth and completion of the hepatitis B and 4:3:1:3 vaccine series. , 2000, JAMA.

[10]  M. Pfeffer,et al.  Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein , 1999 .

[11]  J. Tardif,et al.  Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. , 1999, Circulation.

[12]  P M Rautaharju,et al.  NOVACODE serial ECG classification system for clinical trials and epidemiologic studies. , 1992, Journal of electrocardiology.

[13]  G. Davı̀,et al.  Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[14]  D. Green,et al.  Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. , 1997, Circulation.

[15]  D. Waters,et al.  Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. , 1995, Circulation.

[16]  M. Ezekowitz,et al.  Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. , 1998, The American journal of cardiology.

[17]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[18]  N. Alpert,et al.  Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse. , 1998, Circulation.

[19]  J. Egido,et al.  HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. , 1998, Journal of the American College of Cardiology.

[20]  L. Wallentin,et al.  Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study , 1999 .